Bilateral Ovarian Thecoma in a Postmenopausal Woman with Rapidly Progressed Severe Hyperandrogenism

Garzia E1,*, Galiano V1-2 and Marconi AM2

1Reproductive Medicine Unit, ASST Santi Paolo e Carlo, San Paolo University Hospital, Milan, Italy
2Obstetrics and Gynecology Unit, ASST Santi Paolo e Carlo, San Paolo University Hospital, Milan, Italy

1. Abstract
1.1. Aims: Sex cord-stromal neoplasms of the ovary are an infrequent cause of androgen excess and virilization in women. We report a case of a 60 years old woman with rapidly progressive signs of virilization and indeterminate pelvic masses at computed tomography imaging.
1.2. Methods: The patient underwent a complete hormonal profile and to a non conclusive transvaginal ultrasonography and a pelvic computed tomography scan.
1.3. Results: Hormonal serum assays revealed markedly increased serum Testosterone and Δ-4 Androstenedione concentrations whereas Dehydroepiandrosterone-sulfate (DHEA-S) levels were found below the reference interval. An ovarian source of androgens was suspected and therefore performed the bilateral oophorectomy. Ovarian histology demonstrated a bilateral ovarian thecoma.
1.4. Conclusion: Our report highlights the importance of a careful evaluation of the hormones source in a case of postmenopausal androgen excess in order to ensure the patient a suitable and prompt treatment.

3. Introduction
Androgen-secreting ovarian tumors are an infrequent cause of androgen excess in women, with the greatest prevalence of one case every 500 women presenting with clinical hyperandrogenism (0.01-0.25%) [1]. Ovarian thecoma is a rare benign tumor of stromal cell origin which generally occurs in peri- and post-menopausal decades as a unilateral, benign, solid lesion. It represents less than 1% of all ovarian neoplasms [2-5] and is classified within the sex cord-stromal ovarian tumor category. The histology of ovarian thecoma is characterized by clusters of large, rounded or polyhedral cells and sometimes may embody luteinized cells able to produce steroid hormones [6].Typical thecomas are almost always estrogenic; the virilization due to the hyperandrogenemia caused by a luteinized thecoma in postmenopausal women is extremely rare (about 10% of all the cases) [7]. In this case report we present the unusual case of a 60 years-old woman with a rapidly progressed hirsutism and male-pattern baldness whose pathology was post-surgery diagnosed as a bilateral luteinized ovarian thecoma.

4. Case Report
A 60 years-old Italian woman referred to the gynecological endocrinology outpatient clinic of San Paolo University Hospital in Milan presenting an eighteen months history of progressive fronto-temporal alopecia and whole-body hirsutism. Previously she had always experienced good health. She got married early and at the age of 18 and 23, delivered vaginally two healthy sons. She was an heavy smoker (approximately 20 cigarettes per day) since she was 30; at 41 she underwent a laparotomic hysterectomy with ovaries preservation, for symptomatic multiple uterine myomas; 2 years before she was diagnosed to have hypertension treated with Ramipril and Amlodipine with a good control of blood pressure.

Physical examination showed class 1 obesity (BMI 31.11 kg/m2), severe hirsutism mostly involving face, chin and chest (score 26 of the modified Ferriman and Gallwey test), and severe hair loss, presenting as a diffuse hair thinning with a male pattern baldness area on the crown (Ludwig score III). The gynecological examination showed regular external genitalia and the lack of appreciable pelvic masses. The patient underwent a complete hormonal profile: prolactin and Thyroid Stimulating Hormone (TSH) levels were normal, serum Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH), and estradiol concentrations, were within the normal range for age, 24 mIU/mL, 44 mIU/mL and 63 pg/mL respectively. On the contrary, serum testosterone concentration (2.91 ng/mL) and Δ-4 Androstenedione levels (4.63 ng/mL) were markedly increased, while dehydroepiandrosterone-sulfate (33 µg/100mL) was under expressed. Because
of sex hormone binding globulin (SHBG) concentration of 23,94 nmol/L, a Free Androgen Index of 42,18% was calculated. The investigation of the Hypothalamic-Pituitary-Adrenal (HPA) Axis Function Revealed Adrenocorticotropic (ACTH), basal cortisol levels, 24-hour Urinary Free Cortisol (UFC) and urinary 17-ketosteroids levels in the normal range.

Transvaginal ultrasound examination showed regularly positioned ovaries, bilaterally enlarged in the absence of clear ultrasonographic signs of ovarian cysts or solid masses but showing a diffuse inhomogeneous hypoechoic echotexture and no clear signs of vascularization on color Doppler investigation (color Score 1-2). The ovaries volume was 4,6 cm³ for the right ovary and 5,5 cm³ for the left ovary, while the longest diameter was respectively 35 mm and 34 mm. These ultrasonographic features, although not attributable to a specific ovarian disease, conflicted to the patient’s age. Ovarian tumor markers serum dosages (CA 125, CA 19.9, CEA, β-hcG and AFP) were within the normal range.

Abdominal and pelvic Computed Tomography (CT) scans suggested the presence of two solid pelvic masses measuring about 3 cm in diameter. The masses were well-demarcated, roundish, well-enhanced and with corrugated margins. No pathologic findings in other abdominal or pelvic organs were identified nor ascites. Iliac-obturator lympho-nodal enlargement in the site of right iliaca artery was detected. The Magnetic Resonance Imaging (MRI) screening for possible pituitary lesions was negative.

In the suspicion of an androgen-secreting ovarian tumor, a laparoscopy with bilateral salpingo-oophorectomy was performed. The macroscopic examination showed, for both ovaries, a plurinodular brownish-yellow appearance, with multiple gray-brownish fragments in the context. Extemporaneous histological examination revealed the presence of bilateral solid benign fibro-stromal lesions. The peritoneal fluid cytology for malignant tumor cells resulted negative. The definitive histological examination was compatible with bilateral ovarian fibro-thecoma, with aspects of luteinized thecomas, described as nests of pale luteinized cells within proliferating spindled cells arranged in fascicles with scant cytoplasm.

Immunistochemical expression analysis revealed a coherent positivity for Inhibin-alpha. The postoperative course was uncomplicated and the patient was discharged on the fourth day after surgery.

Twelve weeks after surgery the seric androgen levels returned into the normal range and the patient reported a gradual improvement of clinical symptoms: serum Testosterone and Androstenedione levels respectively decreased to 0,14 ng/mL and 0,55 ng/mL with DHEA-S levels normalization (150 µg/100mL).

5. Discussion

Virilization due to hyperandrogenemia is an uncommon possibility in postmenopausal women and particularly if hyperandrogenemia is caused by a luteinized ovarian thecoma. Ovarian thecomas are very infrequent ovarian tumors [8]. They occur mostly in peri- and postmenopausal women, with a mean age of 45, rarely malignant, bilateral in 3% of cases [9].

The clinical presentation is relatively non-specific, usually represented by pelvic discomfort or pain. If hormonally active, they usually secrete estrogens that lead to endometrial hyperplasia and clinically presents with menstrual irregularities or postmenopausal bleeding. Androgenic manifestations are rarely reported and are restricted to the tumors characterized by luteinized cells, as is observed in 10% of thecomas, producing androgens and leading to virilization [7, 10].

Androgen secretion of an ovarian tumor before menarche results in heterosexual precocity with premature pubarche, clitoromegaly, virilizing manifestations and accelerated somatic growth. During reproductive age, the typical picture of androgen secretion is oligoamenorrhea and progressive virilization through hirsutism, alopecia, clitoromegaly and deepening of the voice. Post-menopausal women only occasionally develop signs of virilism, mostly represented by hirsutism and fronto-temporal baldness [11]. Not all patients with elevated serum testosterone levels display androgenic alopecia. This may be related to individual differences in the sensitivity of hair follicles to the dihydrotestosterone (DHT) activity.

The great part of the published cases of luteinized thecomas in postmenopausal women show different presentation of the disease [3,8,10]. In the present case hirsutism and male pattern hair loss developed in a relatively short period of time.

A full endocrinological laboratory evaluation is mandatory in patients with clinical hyperandrogenism, in order to detect the androgen excess source and to exclude all the possible endocrinopathies hyperandrogenism-related.

It has been suggested that a single serum testosterone measurement above 2ng/mL may indicate the presence of an androgen secreting tumor [12]. Therefore, a serum testosterone level of 2.9 ng/mL, as we found in our patient, was strongly indicative of the necessity to detect rapidly the source of androgen excess.

Despite the 2 years presence of hypertension could be suggestive of an adrenal involvment, adrenal masses or Cushing’s disease were excluded by the abdominal ultrasound scan and the biochemical tests. Furthermore, the disagreement between Testosterone and DHEA-S levels and the concordance with those of Androstenedione Δ-4 clearly oriented on the ovarian origin of the hormones.

The investigation of ovarian fibro-thecomas is based, like all ovarian masses, on ultrasound examination. A broad spectrum of sonographic features is reported. At sonography these types of tumors are usually described as hypoechoic adnexal masses manifesting minimal or moderate blood flow on color Doppler examination.
with slightly irregular internal echogenicity and stripy shadows and
with or without cystic spaces. Larger tumors are often associated
with torsion, hemorrhage, calcification, or complicated with other
cystic lesions in mixed echogenic masses. Many women have fluid
in the pouch of Douglas [13].

In the present case transvaginal ultrasonography was not greatly
helpful, displaying two ovaries with only moderately increased vol-
ume with uniform hypoechogenic appearance: a parophysiological
significance given the woman’s age. No ovarian masses were clearly
visualized and also the markers were negative. The rarity of a bilat-
eral secretory tumor made the diagnosis even more difficult.
However, the belief that the disease was of ovarian origin has led to
more detailed investigations. The first line therapy of a luteinized
thecoma is surgery. Ovarian mass resection is indicated for wom-
en in reproductive age who need to preserve fertility and similarly
it is recommended in postmenopausal women against a potential
ovarian malignancy.

Thecomas generally behave benignly, albeit features such as mi-
totic rate, hemorrhage and necrosis in the mass context should be
regarded with caution for fibrosarcomas. Testosterone levels can
be used as a marker of complete excision and for monitoring the
subsequent disease course.

6. Conclusion
This report illustrates a case of virilizing ovarian tumor able to
elude the first line medical imaging techniques. It emphasizes the
potential pitfalls that may occur in the preoperative evaluation of
patients with markedly increased androgens production. Hormo-
nal assays can often guide the physicians to the source of androgen
secretion and lead to the proper diagnosis and treatment, resulting
in the fairly accurate clinical case management.

References
1. Carmina, E., F Rosato, A Jannì, M Rizzo, R A Longo. Exten-
sive clinical experience: relative prevalence of different andro-
gen excess disorders in 950 women referred because of clinical
hyperandrogenism. The Journal of clinical endocrinology and

ovary: a comprehensive review and update for radiologists. Di-
agnostic and interventional radiology (Ankara, Turkey), 2015;

3. Takemori, M., R. Nishimura, and K. Hasegawa. Ovarian the-
coma with ascites and high serum levels of CA125. Archives of

4. Chen H, Liu Y, Shen LF, Jiang MJ, Yang ZF and Fang GP. Ovar-
ian thecoma-fibroma groups: clinical and sonographic features
with pathological comparison. Journal of ovarian research,

5. Burandt, E. and R.H. Young,. Thecoma of the ovary: a report
of 70 cases emphasizing aspects of its histopathology different
from those often portrayed and its differential diagnosis. The
American journal of surgical pathology, 2014; 38(8): p. 1023-
1032.

tumors containing lutein or Leydig cells (luteinized thecomas
and stromal Leydig cell tumors)--a clinicopathological analysis
of fifty cases. International journal of gynecological pathology :
official journal of the International Society of Gynecological

7. Keeney G, Ovarian tumors with endocrine manifestations. En-
docrinology. 4th ed. Philadelphia (PA): WB Saunders Compa-
y, 2001; 2172.

Ovarian thecoma with androgenic manifestations in a post-
menopausal woman. Gynecological endocrinology : the official
journal of the International Society of Gynecological Endocri-
nology, 2006; 22(7): p. 405-408.

9. Chen VW, Ruiz B, Killeen JL, Coté TR, Wu XC, Correa CN, Howe HL.Pathology and classification of ovarian tumors. Can-

Luteinized ovarian thecoma in a postmenopausal women pre-
senting with virilization. Obstetrics and gynecology interna-

11. Aboud E, J Crow and H Gordon. Sex cord-stromal tumours of
the ovary- a 25 year review. Journal of obstetrics and gynaecol-
ogy : the journal of the Institute of Obstetrics and Gynaecology,


13. Paladini, D, A Testa, C Van Holsbeke, R Mancari, D Timmer-
man, I. Valentin Imaging in gynecological disease (5): clinical
and ultrasound characteristics in fibroma and fibrothecoma of
the ovary. Ultrasound in obstetrics & gynecology : the official
journal of the International Society of Ultrasound in Obstetrics